Can Fam-trastuzumab deruxtecan-nxki treat lung cancer?

Fam-trastuzumabFam-trastuzumab deruxtecan-nxki is a prescription drug used to treat adults with non-small cell lung cancer (NSCLC) who have a certain mutation in the HER2 gene that cannot be removed with surgery or has spread to other parts of the body and who have received prior treatment. Medical staff will perform a test to make sure deruxtecan is right for the patient.

The U.S. Food and Drug Administration (FDA) approved trastuzumab for this use based on a clinical study that measured how many patients responded and how long they took to respond. Preliminary analysis results from the DESTINY-lung 02 phase II trial show that trastuzumab demonstrated strong and durable tumor responses. The confirmed objective response rates (ORR) of the 5.4 mg/kg group and the 6.4 mg/kg group were 49.0% and 56.0% respectively. The safety profile of both doses was consistent with the overall safety profile of trastuzumab, with the 5.4 mg/kg dose demonstrating a good safety profile in this patient population. Secondary endpoint data are also encouraging, with trastuzumab showing median PFS of 9.9 months and 15.4 months in the 5.4mg/kg and 6.4mg/kg groups, respectively, as assessed by BICR. At the time of analysis, the 5.4 mg/kg group had achieved a median OS of 19.5 months, while the 6.4 mg/kg group had not.

Detrastuzumab is a new type of injectable anti-cancer drug. The original drug has been marketed in China, but it has not yet entered the scope of medical insurance. It is a strictly controlled drug. The domestic price is not yet clear. The Hong Kong version of Detrastuzumab Specifications may cost more than 10,000 yuan per box of 100mg. The Hong Kong original version of Detrastuzumab may be more than RMB 10,000 per box. Tocilizumab Specifications of the original drugThe price of 100mg per box may be around 15,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of the two drugs are basically the same. There is currently no generic version of trastuzumab on the market. For more specific prices and drug information, please consult the medical consultant of the drug.